Clinical trial
3-AP in Treating Patients With Advanced Cancer
NCT00006218 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00006218 |
|---|---|
| Title | 3-AP in Treating Patients With Advanced Cancer |
| Official title | A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Cancer Patients Using a 96-Hour Intravenous Continuous Infusion |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | triapine |
| Start date | May 1, 2000 |
| Completion | Jan 1, 2008 |
| First posted | Mar 17, 2004 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: